Source comparison
PT-141 for Appetite Control Research: [Peptide] Comparison
The table below compares PT-141 to other peptides frequently evaluated in appetite control research, focusing on receptor mechanism, efficacy metrics, dosing requirements, and tolerability profiles. PT-141 (bremelanotide) MC3R/MC4R agonist (central melanocorti
This comparison does not assign a generated winner or score.
- The table below compares PT-141 to other peptides frequently evaluated in appetite control research, focusing on receptor mechanism, efficacy metrics, dosing requirements, and tolerability profiles.
- PT-141 (bremelanotide)
- MC3R/MC4R agonist (central melanocortin pathway)
- 12–17% over 28 days (human study, Obesity Res Clin Pract 2021)
- 2.7 hours
- Daily to every 48 hours (subcutaneous)
- Transient hypertension (10–15 mmHg systolic increase), facial flushing, headache in ~40% of users
- Modest central appetite modulation with significant inter-individual variability; not optimized for metabolic use
- Semaglutide (GLP-1 agonist)
- GLP-1 receptor agonist (delays gastric emptying, enhances satiety)
- 20–30% sustained reduction (STEP-1 trial, 68 weeks)
- ~7 days
- Weekly (subcutaneous)
- GI side effects (nausea, vomiting, diarrhea) in 30–45% during titration; resolves in most cases
- Gold standard for appetite suppression and weight loss; FDA-approved for chronic weight management
- Tirzepatide (dual GIP/GLP-1 agonist)
- GLP-1 + GIP receptor co-agonist (enhanced incretin effect)
- 25–35% sustained reduction (SURMOUNT-1, 72 weeks)
- ~5 days
- Similar GI tolerability profile to semaglutide; slightly higher nausea incidence at max dose
- Superior efficacy to semaglutide in head-to-head trials; strongest appetite suppression currently available
- Liraglutide (GLP-1 agonist)
- GLP-1 receptor agonist (gastric emptying delay)
- 15–20% over 56 weeks (SCALE trial)
- ~13 hours
- Daily (subcutaneous)
- GI side effects similar to semaglutide but more frequent due to daily dosing
- Effective but logistically less convenient than weekly GLP-1 options
- GHRP-2 (growth hormone secretagogue)
- Ghrelin receptor agonist (increases appetite)
- Increases food intake by 20–30% in research settings
- 20–30 minutes
- Multiple daily doses (research context)
- Significant hunger stimulation; water retention; transient hyperglycemia
- Used in research to study ghrelin's role; opposite effect to appetite suppressants